Island Pharmaceuticals Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ILA.AX research report →
Price Chart
About the company
Island Pharmaceuticals Limited functions as a pharmaceutical enterprise dedicated to drug discovery and repurposing, with a specific focus on creating preventative or therapeutic solutions for viral infections. Its lead therapeutic agent, ISLA-101, is currently under development for both preventing and treating dengue fever and other illnesses transmitted by mosquitoes. The company participates in various strategic collaborations, including a research partnership with Monash University to evaluate known molecules against host targets, and a research and development alliance with Griffith University aimed at screening for active antiviral compounds through a systematic repurposing approach.
- CEO
- David Charles Foster
- IPO
- 2021
- HQ
- Hawthorn East, VIC, AU
Get TickerSpark's AI analysis on ILA.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $145.00M
- P/E
- -15.96
- Fwd P/E
- 0.38
- PEG
- 0.65
- P/S
- 6570.57
- P/B
- 17.34
- EV/EBITDA
- -18.73
- Div Yield
- 0.00%
- Gross Margin
- -3306.08%
- Op Margin
- -36720.03%
- Net Margin
- -32617.60%
- ROE
- -100.58%
- ROIC
- -112.40%
Latest fiscal year · YoY change
- Revenue
- $118.91K-90.5%
- Gross Profit
- $-1,285,921-27.2%
- Op Income
- $-5,359,853
- Net Income
- $-3,920,139-36.9%
- EPS
- $-0.02+28.7%
- OCF Growth
- +12.5%
- FCF Growth
- +12.5%
- 52W High
- $0.63
- 52W Low
- $0.20
- 50D MA
- $0.42
- 200D MA
- $0.41
- Beta
- 0.12
- RSI (14)
- 65
- Avg Volume
- 285.06K
No earnings-call transcripts are available for ILA.AX yet.
- Free Float
- 103.6%
- Shares Outstanding
- 295.92M
- Float Shares
- 306.65M
Our ILA.AX coverage
Recent articles, reports, and earnings notes.
No research on ILA.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ILA.AX report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.